American Century Companies
ENGN icon

American Century Companies’s enGene Therapeutics ENGN Stock Holding History

American Century Companies’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$224K Buy
32,861
+8,881
+37% +$79.1K ﹤0.01% 2689
2025
Q4 		$217K Buy
+23,980
New +$192K ﹤0.01% 2696

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

American Century Companies's ENGN Position: Q1 2026 in Review

American Century Companies increased its enGene Therapeutics (ENGN) stake by 37% in Q1 2026, buying an estimated $79.1K and bringing the position to 32,861 shares worth $224K. The position accounts for ﹤0.01% of the portfolio, ranked #2689.

American Century Companies first reported a position in ENGN in Q4 2025 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • American Century Companies held 32,861 shares of enGene Therapeutics worth $224K as of Q1 2026.
  • American Century Companies bought 8,881 enGene Therapeutics shares in Q1 2026, an estimated $79.1K.
  • enGene Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q1 2026, its #2689 holding.
  • American Century Companies first reported a position in enGene Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on American Century Companies's 13F filing for Q1 2026, filed 15 May 2026.